Stanford announces new Center for Definitive and Curative Medicine – Stanford Medical Center Report

It is a privilege to lead the center and to leverage my previous experience to build Stanfords preeminence in stem cell and gene therapies, said Roncarolo, who is also chief of pediatric stem cell transplantation and regenerative medicine, co-director of the Bass Center for Childhood Cancer and Blood Diseases and co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Stanford Medicines unique environment brings together scientific discovery, translational medicine and clinical treatment. We will accelerate Stanfords fundamental discoveries toward novel stem cell and gene therapies to transform the field and to bring cures to hundreds of diseases affecting millions of children worldwide.

The center consists of several innovative pieces designed to allow the rapid development of early scientific discoveries into the clinic that in the past have languished. This includes an interdisciplinary team of basic and clinical scientists to shepherd nascent therapies developed at Stanford. The team will be headed by associate directors Matthew Porteus, PhD, associate professor of pediatrics, and Anthony Oro, MD, the Eugene and Gloria Bauer Professor and professor of dermatology.

To help with clinical development, the center boasts a dedicated stem cell clinical trial office with Sandeep Soni, MD, clinical associate professor of pediatrics, as medical director. In addition, the center has dedicated clinical trial hospital beds in the Bass Center for Childhood Cancer and Blood Diseases located on the top floor of the soon-to-open LucilePackardChildrensHospital. From work performed by scientists over the past decade, the center already has a backlog of nearly two dozen early stage therapies whose development the center will accelerate.

The center will provide novel therapies that can prevent irreversible damage in children, and allow them to live normal, healthy lives, said Mary Leonard, MD, professor and chair of pediatrics and physician-in-chief at Stanford Childrens Health. The stem cell and gene therapy efforts within the center are aligned with the strategic vision of the Department of Pediatrics and Stanfords precision health vision, where we go beyond simply providing treatment for children to instead cure them definitively for their entire lives.

One of the unique features of the center is its close association with the recently opened $35 million Stanford Laboratory for Cell and Gene Medicine, a 23,000-square-foot manufacturing facility located on California Avenue in Palo Alto. One of the first of its kind in the world, the laboratory has the ability to produce newly developed cell and gene therapy therapies according to the Good Manufacturing Practice standards as required for patient treatment.

Headed by executive director David DiGiusto, PhD, the lab can produce diverse cellular products for patient use, such as genetically corrected bone marrow cells for sickle cell anemia, genetically-engineered skin grafts for children with the genetic disease epidermolysis bullosa or genetically-engineered lymphocytes to fight rejection and leukemia.

We are fortunate that Stanford researchers have created such a strong portfolio of innovative candidate therapeutics to develop, said DiGusto. The capabilities of the laboratory will bridge the gap between research and clinical investigation so that the curative potential of these exciting cell and gene therapies can be realized.

For more information about the center, or for information about trials associated with the center, please see https://med.stanford.edu/ptrm/faculty.html, or contact Jennifer Howard at jmhoward@stanford.edu.

Continue reading here:

Stanford announces new Center for Definitive and Curative Medicine - Stanford Medical Center Report

Stealth BioTherapeutics Initiates Phase 2/3 Study of Elamipretide in Patients With Barth Syndrome – Markets Insider

BOSTON, July 24, 2017 /PRNewswire/ --Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced the initiation of TAZPOWER, a Phase 2/3 study evaluating elamipretide in patients with Barth syndrome. Barth syndrome is a rare genetic mitochondrial disease, caused by mutations in the TAZ gene, and characterized by cardiac abnormalities, skeletal muscle weakness, recurrent infections and delayed growth.

"The severe problems experienced by patients with Barth syndrome are caused by misshapen and dysfunctional mitochondria, which reduce the energy production in the affected tissues. The resulting muscle weakness can lead to severe fatigue, heart failure and death," said Stealth Chief Medical Officer Doug Weaver. "In this study, we hope to show that elamipretide may have clinical benefit by improving function in these affected mitochondria."

TAZPOWER is a randomized, double-blind, placebo-controlled crossover study that will evaluate the effects of daily elamipretide treatment in a minimum of 12 patients with genetically confirmed Barth syndrome. Patients will be randomized to one of two sequence groups: 12 weeks of single daily subcutaneous injections of elamipretide in Treatment Period 1, followed by 12 weeks of treatment with placebo in Treatment Period 2, with a four-week wash-out period between periods, or vice versa. The primary endpoint is change in distance walked during the six-minute walk test. Secondary endpoints include functional assessments, patient-reported outcomes and safety.

"Our understanding of Barth syndrome and how it manifests has evolved significantly, but current treatment efforts are still limited to the management of symptoms," said Hilary Vernon, M.D., Ph.D., assistant professor of Pediatrics at McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University and the primary investigator for the study. "The initiation of TAZPOWER represents an important milestone in the potential development of a disease-specific treatment option."

TAZPOWER builds upon Stealth BioTherapeutics's existing rare disease and cardiorenal programs, including three ongoing Phase 2 studies in adults with heart failure (IDDEA-HF, PROGRESS-HF, RESTORE-HF).

"This study underscores our commitment to develop elamipretide for the treatment of rare genetic mitochondrial diseases," said Stealth Chief Executive Officer Reenie McCarthy. "The cardiovascular and skeletal muscle symptoms affecting this population share a common thread with symptoms experienced in diseases commonly associated with aging, such as heart failure, in which mitochondrial dysfunction contributes to the clinical pathology."

For additional information on the TAZPOWER study or elamipretide, please refer to Stealth's website.

About Barth Syndrome Barth syndrome is a rare genetic condition characterized by muscle weakness, cardiac abnormalities, recurrent infections and delayed growth. Barth syndrome occurs almost exclusively in males and is estimated to affect one in 200,000 to 400,000 individuals worldwide at birth. There are currently no FDA-approved therapies for the disease.

About Stealth BioTherapeutics We are a privately held clinical-stage biotechnology company focused on the development of therapeutics for diseases involving mitochondrial dysfunction. We believe there is a strong rationale for our lead product candidate,elamipretide, in indications in these diseases based on encouraging preclinical and early clinical data. We are investigating elamipretide in three primary mitochondrial diseases primary mitochondrial myopathy (PMM), Barth syndrome and Leber's hereditary optic neuropathy (LHON) as well as in heart failure, Fuchs' corneal dystrophy and dry age-related macular degeneration.We received Fast Track designation for elamipretide for the treatment of PMM from the FDA in December 2015. We are developing our second product candidate, SBT-20, for central nervous system disorders.Our mission is to be the leader in mitochondrial medicine. To learn more information about us and our pipeline, visitwww.stealthbt.com.

Contacts Media Relations dna Communications Kate Contreras, 617-520-7088 rel="nofollow">Media@StealthBT.com

Investor Relations Stern IR Beth DelGiacco, 212-362-1200 rel="nofollow">IR@StealthBT.com

View original content with multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-initiates-phase-23-study-of-elamipretide-in-patients-with-barth-syndrome-300492467.html

SOURCE Stealth BioTherapeutics

View post:

Stealth BioTherapeutics Initiates Phase 2/3 Study of Elamipretide in Patients With Barth Syndrome - Markets Insider

Asia Lung Cancer Summit in Hong Kong Targets Precision Medicine – PR Newswire (press release)

The event was held at Hong Kong Science Park and was co-organised by Hong Kong Cancer Therapy Society, the Hong Kong Association of Community Oncologists, the Hong Kong Society of Clinical Oncology, and supported by Hong Kong Science and Technology Parks Corporation and AstraZeneca. The Scientific Collaboration Partner of the conference is Sanomics Ltd., a start-up in Hong Kong Science Park specialising in blood-based genomics technologies for cancer patients.

Lung cancer is the leading cause of cancer deaths worldwide, claiming more than 1.6 million lives each year-- more than breast, colon and prostate cancer combined. Not only smokers get lung cancer but about 51% of the world's lung cancer cases occur in Asia[1], while it accounts for 21% of cancer deaths in the region[2]. In addition to the current treatment approaches precision medication uses DNA analysis for early detection of cancer and to identify therapies that are tailored for individual patients has become an emerging added solution in the cure of lung cancer.

The well-timed conference drew experts in Asia to discuss and examine the progress of high quality biomarker testing in the region. It also put heavy emphasis on the need for collaboration and why Hong Kong, with its expertise in precision medicine, genome analysis and nano-technology in the field of cancer management, is a natural regional hub for research, development, clinical application and investments in this field.

Genomics biomarkers essential for personalised cancer management

Mrs. Fanny Law, Chairperson of Hong Kong Science and Technology Parks Corporation, in an opening address at the conference, said advances in precision medicine have transformed healthcare and treatment of diseases. Predictive diagnosis and personalised treatment tailored to each person's genetic makeup and the genetic profile of the tumour can enhance efficacy and minimise adverse effects.

"Precision medicine faces many challenges in clinical application and this requires collaboration between all stakeholders," said Mrs. Law. "The therapeutic prospects of precision medicine are enticing, spurring enterprising researches around the world. Today genetic testing is available for over 2,000 clinical conditions and the number of available diagnostic test is increasing exponentially."

Mr. Tony Yung, Chief Executive of Sanomics, said: "Our work on precision medicine effectively supports the decision-making of oncologists based on information about genetic alternations in tumour DNA. Once clinically significant genetic alternations are identified, specific treatments can be aimed at the tumours. These have a much higher chance of achieving desirable clinical outcomes."

Hong Kong has a key role in research and dissemination of knowledge on cancer

"The uniqueness of Sanomics' approach is making use of bodily fluids, such as blood, to screen for genetic alternations when tumour tissues are not available. We call it "liquid biopsy", which is faster, less risky, more convenient and more practical in the clinical setting. We are now building Asia's first hub for liquid biopsy here in Hong Kong, and will lead the region in the use of genomics for personalized management of cancer," said Mr. Yung. "The breakthroughs we achieved not only exemplify the research and development excellence of Hong Kong's biomedical experts but also our strengths to identify and resolve challenges for the Asia healthcare sector."

Hong Kong Science Park has more than 80 biotechnology companies with business scope that spreads across medical devices, research on stem cells, genomics and regenerative medicine, molecular diagnosis, as well as R&D on Chinese and Western medicines. All of these, in their differing ways, contribute to an ecosystem that's highly conducive to research. Importantly, clinical data from Hong Kong is recognised by the China Food and Drug Administration (CFDA) for registration and approval purposes, making it an ideal testing ground for emerging therapies and devices.

"A year ago,the CFDAaccredited two phase 1 clinical trial centres in Hong Kong andaccepted clinical trial data from Hong Kong for registration and approval purposes," said Mrs. Law. "Looking to the future, we must all seize the opportunities arising from the Hong Kong Shenzhen Innovation Technology Park along the border between the two cities and the Guangdong-Hong Kong-Macau Greater Bay Area to enlarge Hong Kong's capacity for biomedical research and development to meet the growing demand for better health care for the ageing population both in Hong Kong and Mainland China."

"Our aspiration is for the Greater Bay Area to be an innovation hub with global impact. And within this area, the Hong Kong-Shenzhen Innovation and Technology Park will be a powerhouse of research where great minds from Mainland China, Hong Kong and the rest of the world meet and work together," continued Mrs Law.

Besides Mrs. Law and Mr. Yung, other keynote speakers at the conference included: Prof. Tony Mok, Chairman, Department of Clinical Oncology at the Chinese University of Hong Kong; Mr. Leon Wang, EVP, International & China President of AstraZeneca (China); and Prof. Yilong Wu, Director of Guangdong Lung Cancer Institute and Vice-president of Guangdong General Hospital (China).

[1] Source: World Cancer Report 2014.Steward, Bernard and Wild, Christopher (eds). (2014)

[2] Source: World Health Organization. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012 (2015): http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

About Hong Kong Science and Technology Parks Corporation

Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.

Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.

Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long.

More information about HKSTP is available at http://www.hkstp.org.

View original content with multimedia:http://www.prnewswire.com/news-releases/asia-lung-cancer-summit-in-hong-kong-targets-precision-medicine-300493458.html

SOURCE Hong Kong Science and Technology Parks Corporation

http://www.hkstp.org

See the rest here:

Asia Lung Cancer Summit in Hong Kong Targets Precision Medicine - PR Newswire (press release)

Patient-Centered Vs. Lab-Centered ‘Personalized Medicine’ – HuffPost

It is more important to know the patient who has the disease than the disease the patient has. Hippocrates

Personalized medicine was invented 2500 years ago when Hippocrates put the patient at the center of medical care- not the gods or the practitioner or the treatment.

To the detriment of patients, Hippocrates brand of patient centered, personalized medicine has been eroded by 150 years of increasingly high tech medicine. Sadly, the laboratory tests, the technical tools, the medical record, the billing system, and the computer are now too often at the center of medical care- all at the expense of the crucial healing that has always come from the doctor/patient relationship.

The modern and misleading use of the term Personalized Medicine began 20 years ago as an outgrowth of the enormous enthusiasm engendered by the human genome project.

The concept was grand. Rather than diagnose and treat people based on very broad and nonspecific features (like shared symptoms or signs), perhaps doctors could use the powerful new genetic tests to determine which specific genes were causative of each individuals disease and then fashion a treatment specific to each persons underlying genetic defect.

There have already been a few dramatic successes of this modern form of personalized medicine, and hopefully with time there will eventually be many more.

But scientifically informed personalized medicine mostly remains a distant hope for the future and has instead become a crude form of marketing hype in the present.

Hospitals, drug companies, doctors, the National Institute of Health, even President Obama have used the misleading term personalized medicine as a branding advertising tool to sell medical services and to gain support for enhanced research funding.

Extravagant promises are made that most certainly cannot possibly be kept. The sell is that magical cures for a whole variety of diseases are just around the corner- especially now that we have the extremely powerful tool of gene editing.

The reality is much more uncertain and difficult. Most diseases have remarkably complex genetic roots involving hundreds of genes, each making tiny and complexly interacting contributions. There are few simple genetic targets; there will be few magical cures. Gene editing will likely be helpful only for the relatively few diseases that have simple causation.

Surely, we should march on with sophisticated research to find them, but mustnt be so dazzled by the potential of the science of medicine that we lose the magic that has always come from its art and humanity.

Nicholas Capozzoli, a neurologist, is the wisest and most humane doctor I know. He will help us recapture the simple things, now so often lost, that have made Hippocratic medicine so effective for so long.

Dr. Capozzoli writes: The once-glorious doctor/patient relationship is being cheapened into a commercial contract- like buying a car or filling out tax forms with an accountant. In my view, the tie between doctor and patient should be a powerful relationship of trust, empathy, and healing.

Personalizing medicine by focusing on the patient is an extension of the ancient and time honored tradition of hospitality. The magic of healing in the doctor-patient relationship begins with the first phone call and continues through every contact.

Your patient should be welcomed like an honored guest, not made to feel like an annoying intruder. Greeting someone in the waiting room and escorting them back to your office seems to be a lost art, but should be as natural as greeting people at the door of your home when they arrive for dinner.

Similarly, apologizing for being late is a simple courtesy that should not be forgotten just because the meeting occurs in a professional setting.

While these gestures may seem small, patients often tell me how surprising and comforting they are. They are much more likely to engage in the intimate conversation that informs medical diagnosis when they feel at home with the doctor.

The onerous demands of protocol-driven medicine and electronic medical records have made the filling out of checklists more important to many doctors than really getting to know the person and understanding the context surrounding his symptoms.

Casual conversation is intrinsic to all human relationships and essential in setting the stage for meaningful history taking. The physician paying close attention to the little details can make an accurate differential diagnosis that usually obviates the need for frequent, expensive, and unnecessary fishing-expeditions of extensive laboratory testing that often turn out to do much more harm than good.

Call me old-fashioned, but referring to patients as healthcare consumers and physicians as healthcare providers degrades their relationship and under-estimates the healing it provides.

I take my own vital signs. Patients are surprised by this and tell me it indicates my interest in them.

I take my notes on a yellow pad and only enter whats required for electronic medical records after the patient has left the office. Patients say that other doctors are so focused on the computer screen, they never once make eye contact.

Ushering people into a metallic 8 x 8 room and asking them to undress before the physician even enters seems to be an awkward and humiliating way to start a relationship. My examining table is in my office where I sit down with them for the first time. My office is folksy and filled with conversation pieces. My home becomes temporarily their home.

Arguments that this sort of personalized medicine does not take into account the current business demands of modern medicine simply do not hold water. The quality of the doctor-patient relationship is not identical with the time spent, but rather the way it is spent.

Patients also tell me of rude staff, long waits in the waiting room, and then long waits in the examining area before the physician comes in. This sabotages the doctor-patient relationship and creates a terrible context for care and cure. Administrative handicaps to care can and must be eliminated with careful selection of personnel, ongoing training, and close attention to effective office or clinic management practices. The patients convenience should take priority over staff convenience.

A strong doctor-patient relationship is essential to good diagnosis, to good treatment decisions, to carrying out the treatment plan, and is the royal road toward patient confidence, comfort, and healing. As physicians, we are allowed into a sacred space and must honor our obligation to personalize and humanize all our contacts with patients.

Thank you Dr. Capozzoli for your precious advice on recapturing old fashioned personalized medicine- how best to form a healing doctor/patient relationship.

Which brings us back to the current spate of fake claims for a scientific personalized medicine. Some researchers and leaders of major cancer centers have made the ridiculous promise that all cancers will be cured in 10-20 years. The advertising pitches made by some medical providers are even more outrageous- they make it sound as if personalized medicine has already arrived at their particular hospital.

There has always been a tendency for medicine to overpromise and under deliver. Often enough the treatments offered are more harmful than the diseases treated.

Thats why the Hippocratic First do no harm is the most important commandment in medicine. The second is: Cure sometimes, treat often, comfort always. We shouldnt neglect the bedside art of medicine as we become overly enamored by its laboratory science.

See the original post here:

Patient-Centered Vs. Lab-Centered 'Personalized Medicine' - HuffPost

Geisinger wins grant for research – Sunbury Daily Item

DANVILLE Geisingers Autism & Developmental Medicine Institute (ADMI) has been awarded a one-year, $150,000 grant by the Simons Foundation Powering Autism Research for Knowledge (SPARK) to help advance research into autism.

ADMI will be a center for recruitment and sample collection for a new genetic study that aims to enroll 50,000 individuals with autism and their families nationwide, making it the most ambitious study of the conditions genetics to date.

The one-year grant to ADMI is renewable for a full, three-year term. SPARK is supported by the Simons Foundations Autism Research Initiative.

Approximately 50 genes have been identified that almost certainly play a role in autism, and researchers estimate that at least an additional 300 are involved. But to identify all the genes at play, many more genetic samples are needed from those with autism and their immediate families.

The national autism research project aims to make important progress possible by pooling together tens of thousands of participants for research.

As autism is a spectrum, researchers need many people with autism to participate in all types of research. Until now, only a small number of individuals and families affected by autism have ever participated in research. SPARK wants to invite the entire autism community to dramatically expand its participation.

The medical and genetic data generated from the program will power important new research that aims to advance the understanding of autism and equally provides meaningful information and resources to participants.

As a SPARK site, Geisingers ADMI joins other renowned national autism centers collaborating on this important project, including, for example, Boston Childrens Hospital, Childrens Hospital of Philadelphia, and the UCLA Center for Autism.

If you, or a family member, are affected by autism and want to participate in this vital national research, you may contact Kate Dent at 570-522-9402 or emailkadent1@geisinger.edu.

Geisingers ADMI is led by nationally known expert Christa Lese Martin, Ph.D., and includes many staff working on the cutting edge of research in developmental disorders. In addition, ADMI has a team of physicians, psychologists, genetic counselors, and speech language pathologists to help fulfill its clinical mission.

ADMI works to integrate the diagnosis of children with autism and other developmental disorders with evidence-based interventions, research and training.

For more information on SPARK, see https://sparkforautism.org

View original post here:

Geisinger wins grant for research - Sunbury Daily Item

Bangor Daily News – Bangor Daily News

Wednesday, Aug. 2, 2017 7 p.m. to 8 p.m.

Location: Jesup Memorial Library, 34 Mt. Desert St., Bar Harbor, ME

For more information: 207-288-4245; jesuplibrary.org

Join Dr. Adam Boyko for a talk at the Jesup Memorial Library on Wednesday, August 2 at 7 p.m. The talk is part of the Jesup and The Jackson Laboratorys Genetic Tails series.

Dr. Boyko is an assistant professor at the Cornell University College of Veterinary Medicine. His research focuses on genomic investigation of dogs as a model of genetic disease and evolutionary genetics. One aspect of this work is understanding the evolution and genetics of village dogs, the semi-feral pariah dogs found in much of the world today. His lab, The Boyko Lab, specializes in building tools and resources to uncover the genetic basis of canine diseases and adaptations, develop insights into the history and evolution, and understand the role of natural selection, mutation, and breeding practices on the patterning genetic variation in the dog genome. Dr. Boyko is also the Founder and Chief Science Officer of Embark Veterinary, a canine genetic testing company.

Dr. Boyko is a graduate of the University of Illinois, Urbana-Champaign and received an MS in Computer Science and a PhD in Biology from Purdue University before his postdoctoral research in the Department of Biological Statistics and Computational Biology at Cornell University. He served as a Research Associate in the Genetics Department at the Stanford School of Medicine before beginning his faculty appointment at Cornell in 2011.

This talk is free and open to the public (and their dogs). For more information, contact the Jesup at 207-288-4245 or kchagnon@jesuplibrary.org.

This post was contributed by a community member. Submit your news

Read the original post:

Bangor Daily News - Bangor Daily News

What I learned from home DNA testing – The Guardian

Barbara Ellen using a home DNA-testing kit. Photograph: Sonja Horsman for the Observer New Review for the Observer

There may come a time in everyones life when they find themselves sitting at the kitchen table on an otherwise unexceptional weekday morning, drooling saliva into a test tube in the spirit of scientific inquiry.

The spit is for one of the home genetic-testing kits Im sampling. A growing number of these kits (brands such as 23andMe, DNAFit, Thriva, MyHeritage DNA, and Orig3n) promise to unlock the mystery of your genomes, variously explaining everything from ancestry, residual Neanderthal variants, bioinformatics for fitness, weight loss and skincare, to more random genetic predispositions, denoting, say, the dimensions of your earlobes or the consistency of yourearwax.

More controversially, some of these kits profess to tell you your biological (as opposed to actual age) by measuring the length of your telomeres (in basic terms, the caps at the end of each strand of DNA that protect chromosomes, like plastic tips at the end of shoelaces). Other tests, such as 23andMe, predict higher risks of developing serious conditions, such as multiple sclerosis, Alzheimers and Parkinsons, including the test for BRCA1/BRCA2 (breast and ovarian cancer) that Angelina Jolie famously underwent, going on to have a preventative double mastectomy and surgery to remove her ovaries.

Its easy to do these tests; its usually just a case of collecting your own samples at home, filling in short, basic questionnaires, posting the packages, and then logging on to interactive websites for confidential results (all the kits I tested used outside laboratories). With an array of price ranges and options, from one-off DNA-blitzes to targeting specific health areas, to fitness/wellness tracking, its no surprise that these kits are proving to be very big business and the field is primed to get even bigger, with a global market estimated to be worth around 7.7bn by 2022.

Saying that, whats it all for? Some individuals, such as Jolie, have the kind of family histories that give them good reason to be concerned about their health, though, as becomes clear, those people might be better off consulting doctors in the normal way.

Otherwise, the home-testing kits could be said to fit in with our increasingly health-conscious and, if you wish to be cynical, narcissistic times. What says youre special more than finding out everything about yourself, right down to the nitty-gritty of genetics? In this way, these kits could be viewed as the latest plaything of the worried well. You could see how the scientific approach would appeal to the health-obsessed of all sexes and ages, your marathon runners and serious gym-goers, who take their fitness extremely seriously.

Another key customer type could be people like myself, hurtling through middle age, perhaps just starting to feel the cold bony hand of mortality clamp down on their shoulder. People, who, in the past, may not have exactly prioritised their health, who are starting to wonder what may be in store for them and who are in the (Hypochondriacs R Us) market for some hard-core insight andadvice.

Which is all very well, but do these kits work and deliver the service they promise and what about the wider ethics and implications of home genetic testing? Is it always wise for generally under-informed, under-prepared consumers to meddle in the highly complex, nuanced arena of genetics, risking confusion, complacency or even outright panic and anxiety when confronted with ostensible bad news (which may not even be true)?

The first kit I try is Thrivas baseline test (49), which, like all its products, checks your blood. The box arrives promptly enough (containing spring-loaded needles, a little collection tube, antiseptic wipes, plasters, etc), but theres a problem. The idea is to prick your finger and massage blood into the tube, but I just end up making my fingers sore and what I get out barely smears the top of the phial. Maybe its just me, but it turns into a right faff. In the end, I take advantage of Thrivas service to send someone out to take a sample of blood from my arm.

When we speak, co-founder Hamish Grierson describes Thriva as a lifestyle brand with medical-grade testing at the back end, an opportunity for people to see themselves as consumers rather than patients. Grierson gives examples of people who have benefited from Thriva testing, sometimes picking up early on serious issues. As for alarming people, Grierson says that Thriva has on-site facilities to discuss results and is intended to be complementary to the NHS rather than replacing it: If there are questions we cant answer, were very clear that people should pick it up with their GP.

When my results appear, they show nothing bad. If anything, its anticlimactic: cholesterol, vitamins, liver proteins and the like are all in the normal range, with only ferritin (iron stores) slightly high, with a recommendation to go easy on any iron supplements. My problem with the baseline test is that, unlike Thrivas other products, clients are supposed to have one every three months to keep track, but would I really want (or indeed need) to do such a test soregularly?

According to Margaret McCartney, GP, and author of The Patient Paradox, theres a fundamental problem with home genetic-testing kits per se.

My concern is that more and more of these tests are being put out, and people are being persuaded to have these tests done, and they get results back that are very often of very low value and dubious helpfulness, she says. And often people are told to go to see their GP and that then places a direct stress on the NHS, at no cost to the company. The companies make their profits and walk away, letting the NHS sort out all the fallout, the push-back, from the test results, in a way I find absurd. Why should the NHS have to prop up the problems that these companies create?

In McCartneys view, enough testing is already done in this country (sometimes too much) and there are issues of regulation and informed consent. People are given very dramatic reasons to have these tests it could help save your life, it could help improve the quality of your life but where is the actual controlled evidence that these tests have ever done that? Theres no evidence that says doing these tests makes people becomehealthier.

McCartney says that anxious people often contact her, saying they wished they hadnt done the tests. These companies often say that its worth it for the helpful advice. But I can give you really good advice right now without seeing a single test result: be active, have lots of social networks, do work you enjoy, try not to smoke or drink too much, dont be overweight or underweight, eat lots of fresh fruit and vegetables. Nobody needs to get tests done to get that kind of basic lifestyleadvice.

Nor does McCartney care for the worried well narrative. I dont really like the worried well thing because it moves the blame on to the people themselves. I think people are being made anxious by manipulative advertising. People are generally good. They dont want to be worried or unwell just for fun.

Some concerns about the ultimate efficacy of certain home tests seem to emanate from the industry itself. I did a telomere-measuring test (a mouth swab) by Titanovo, based in north Colorado, which came back saying that my telomeres were too short, putting me at 10 biological years older than I am. However, when I contacted Titanovo, it explained that it had stopped telomere measuring and was now concentrating exclusively on its DNA-utilising bioinformatics health, fitness and wellbeing website (analysing client data from other genetic testing sites).

Titanovo explained that it found telomere measuring too inconsistent, with too many super-fit people presenting with short telomeres and unfit people presenting with long ones and, ultimately, everyone receiving pretty much the same advice: start exercising and eating healthily or continue exercising and eating healthily.

Bill Newman, professor of translational genomic medicine in the Manchester centre for genomic medicine at the University of Manchester, and chair of the British Society of Genetic Medicine, says that such tests in this context simply dont make sense and that, usually, telomere testing would only be used in in-depth studies of ageing and diseases associated with ageing. Theres some really brilliant work going on, by some of the best biologists in the world, says Newman, citing Elizabeth Blackburn, who won the 2009 Nobel prize for medicine for her work on telomeres. But theres no evidence whatsoever that measuring a persons telomeres gives any indication about their health or beauty, intelligence, or anything else that might be listed on these sites.

In Newmans view, the genie is out of the bottle with home genetic-testing kits. He says that while the kits could potentially provide data in the future, right now, they lack clinical utility they look at genetic variants that, individually, have a very low chance of predicting specific health risks, as there are too many variables: Its like the Opportunity Knocks clap-o-meter, with some people further along the scale, and therefore more likely to get the condition and then people at the other end of the scale, who are unlikely to get it.

Newman says that theres a basic lack of literacy and understanding about genetic testing, among the public and even other health professionals. People are given false reassurances or made to panic (just because you have certain genetic variants, it doesnt mean that you will develop a particular condition). Newman also makes the point that, in his field, counselling happens before and after testing and, while people with cancer or heart issues nearly always opt to have the test (as they can then take action to varying degrees), often people with conditions such as Huntingtons disease in their family decide not to go ahead because a diagnosis would change nothing for them. In any event, Newman says that, with genetic testing, while there are different levels, intensive counselling is always absolutely key.

All this comes into sharp focus with the comprehensive kits such as the one provided by 23andMe: the one I drool into a tube for (incidentally, 23andMe doesnt test for Huntingtons disease). Most people, like myself, have a low understanding of genetic variants, what phrases such as higher risk or probability actually mean or how to interpret our results correctly. Is it right that ordinary members of the public must navigate potentially frightening and/or misleading results alone?

As it happens, most of the data on 23andMe seems harmless and fun. There are the Neanderthal variants (I have fewer of them than 58% of 23andMe customers, thank you very much), the bizarre earwax/earlobes-type data and, apparently, I have the muscle composition generally found in elite athletes (fancy). On the downside, my lineage isnt as exotic as Id hoped: 99.1% north-western Europe, of which 71% is British/Irish, with just 0.01% Ashkenazi Jewish to offset the genetic monotony. At 149, the 23andMe kit isnt cheap and Im quite tempted to demand a recount.

Then comes the section about serious genetic variants. So far as counselling goes, previously, Id waved away concern for my psychological welfare from the Observers science editor (Im a former goth, I said. My default setting is doomed), but it turns out to be quite daunting. It doesnt help that I initially mistake the full list of potential conditions for my own results, hence (thankfully briefly) thinking that I have higher risk factors for everything going. It makes me wonder how many other people are going to do that?

In fairness to 23andME, it leaves it up to the customer to unlock the more serious results or not. When I unlock mine, I discover that, while Im not genetically predisposed to such things as the BRAC1 or BRAC2 variant, Parkinsons or MS, I have one of the variants for late-onset (mid-80s) Alzheimers. However, I dont have any other markers for Alzheimers or family history or conditions associated with it or anything else listed in the rather lengthy disclaimer, which also stresses that its not a diagnostic result and to seek further advice from your GP if you are concerned.

This is another feature of these genetic-testing sites they are littered with caveats and disclaimers, forever emphasising that theyre not actual diagnostic tests and, if you are really concerned by your results, to seek further advice from your GP or another health professional. As has been pointed out by McCartney, when anything looks serious, ultimately its back to the very GP and exact NHS infrastructure that these kits profess to smoothly bypass.

As a postscript, I eventually end up having an interesting chat with Titanovo about my bioinformatics (distilled from my 23andMe data). One of the first things Im told is that my eyes are green (theyre brown). However, the bioinformatics got my skin type and frame/weight generally right and had interesting (albeit occasionally generic) things to say about exercise, diet, goals, steering clear of too much sugar and so on.

Who knows how much of it made solid scientific sense? However, I have to confess that I rather enjoyed it on the level of an indulgent genome-oriented pampering session, just as I had a hoot with the ancestry/Neanderthal/earlobe data on 23andMe. Where Thriva is concerned, I also noted that it did advanced thyroid tests. Although such tests are available from the NHS, Im hypothyroid myself and I know that sometimes it can be difficult and time-consuming getting tests repeated and it could be useful to be privately tested in this way.

It could be that, in the main, genetic-testing kits such as these could, if promoted and used responsibly, end up zoned completely away from legitimate science and medicine and placed where perhaps they belong, firmly in the lifestyle-extra zone, if and when people think theyre worth it. Though, somewhat tellingly, when I ask Newman if he thinks that any of the genetic testing kits are worth buying, he instantly says: No. Id say, go to the cinema, watch some sport. Spend the money on something nice, something life-enhancing.

What is the project? The 100,000 Genomes Project is an NHS initiative, run by Genomics England, and is the largest national genome sequencing project in the world. On entering, patients have their entire genome, of more than 3bn base pairs, sequenced. This is different from commercially available genetic testing kits, such as those from 23andMe, which only look at very small stretches of DNA in a process called genotyping. The hope of the NHS is that having so much genetic information, from so many different people, will allow groundbreaking discoveries about how diseases work, who could be susceptible to them, how we can treat them, and what treatments might work.

Whose genomes are being sequenced? The only patients having their genome sequenced are those with certain cancers or rare diseases. In some cases, family members may also be asked to participate. To take part, a patient must first be referred by a consultant, before being taken through an extensive consent process to ensure they know what participation in the project means. As well as the genome sequence, Genomics England asks for access to a patients lifetime medical records so that links can be made between their genetics and their individual disease. The NHS has made it very clear that, for many participants, taking part in this project wont help them treat their disease. But it is hoped that the information they provide will go on to help treat others in the future.

Where does the data go? Each patients genome sequence and their medical records are kept in an NHS data centre in pseudonymised form. Researchers from commercial and not-for-profit organisations can get access to the data at the centre if they can prove that they are using it for studies that will further medical science.

What information do the patients get back? Although the project states that most participants wont receive any useful information, patients will be told if something is found in their genome that is relevant to the treatment, explanation or diagnosis of their condition. They can also choose to learn if they have a genetic risk factor for another disease, such as the BRCA1 gene mutation that can cause breast cancer. Genomics England will only look for risk factors that are linked to a disease that can be treated or prevented. Untreatable conditions, such as Alzheimers, are not looked for.

Why 100,000 genomes? The NHS believes that sequencing 100,000 genomes will provide enough information on these diseases while also being cost-effective. In the future, as the price of whole genome sequencing goes down, it hopes to involve more patients and even more diseases.

Agnes Donnelly

Continue reading here:

What I learned from home DNA testing - The Guardian

Weight-loss surgery helps even the genetic playing field – Lexington Herald Leader


Lexington Herald Leader
Weight-loss surgery helps even the genetic playing field
Lexington Herald Leader
How can one overcome genetics? If everyone in my family is heavy, isn't it a foregone conclusion that I will be heavy also? I hear these concerns often in my office. The good news is we can overcome genetics with weight-loss surgery. The most popular ...

Read the original here:

Weight-loss surgery helps even the genetic playing field - Lexington Herald Leader

Two Recent Scientific Advances Underscore An Encouraging Future For Precision Medicine At FDA – San Marcos Corridor News

Two recent FDA drug approvals point to an encouraging future for precision medicine an approach for disease treatment that tailors medical therapies, including medications, to the needs of individual patients.

By, Janet Woodcock, M.D.

The United States Food and Drug Administration helps bring precision medicine in the form of targeted therapies to people living with diseases that have specific genetic features.

Two recent FDA drug approvals point to an encouraging future for precision medicine an approach for disease treatment that tailors medical therapies, including medications, to the needs of individual patients. These approvals involve diseases resulting from particular genetic characteristics identified by laboratory testing.

FDA has approved many more advances in precision medicines, also called targeted therapies. In the past 3 years alone, our Center for Drug Evaluation and Research has approved more than 25 new drugs that benefit patients with specific genetic characteristics.

And we have approved many more new uses also based on specific genetic characteristics for drugs already on the market. Some of these drug approvals are for patients with rare genetic disorders. Others are new targeted therapies to treat cancer, hepatitis C, or HIV. Medication dosing for specific diseases may also be tailored to the individual.

Precision medicine holds great promise, but to continue developing targeted therapies, we will need scientific advances in the use and development of biomarkers. Biomarkers are indicators in the body that can be measuredlike blood pressure, blood sugar, and tumor size. Tests to identify genetic variants are another form of biomarker.

Biomarkers can enable health care professionals and researchers to identify patients at risk of disease, determine the stage of a disease, and predict the likelihood that a patient will benefit from a drug. They also play a role in drug development.

A particular biomarker, for example, can be used to identify appropriate candidates for a clinical trial, such as those patients likely to respond to treatment.

This can make it easier and faster to recruit patients and may result in a shorter time for drug approval. In a similar way, biomarkers can sometimes identify positive treatment effects before traditional clinical endpoints would.

For instance, biomarkers might show a tumor shrinking before improvement in a patients condition is detected. So, using biomarkers in clinical trials can speed up the time it takes for an investigative drug to reach a patient.

The ability to identify useful biomarkers depends on how well scientists understand the disease they are seeking to treat. In some areas, such as cancer and infectious diseases, we have made real progress in understanding how these diseases develop and how to treat them with drug therapy. FDA continues to encourage drug developers to use strategies based on biomarkers.

One way we do that is by ensuring that a given biomarker is really able to single out those patients who are likely to respond to a specific drug. Another way is using biomarkers to identify people whose disease is progressing rapidly.

Beyond working on biomarkers for individual products, FDA also works with stakeholders and scientific consortia in qualifying biomarkers that can be used in the development of many drugs. Once qualified, these biomarkers may be used in the specified manner by any drug sponsor.

New provisions under the recently passed 21st Century Cures Act provide direction and opportunity for FDA to strengthen the science of biomarkers and to advance precision medicine.

We believe it is important to make drugs such as Kalydeco and Keytruda available to as many patients as can benefit from them. FDA is actively pursuing more advances in targeted therapies.

Janet Woodcock, M.D., is the Director of FDAs Center for Drug Evaluation and Research

Continue reading here:

Two Recent Scientific Advances Underscore An Encouraging Future For Precision Medicine At FDA - San Marcos Corridor News

Personalized medicine focuses on patients’ genetic clues – Newsday

Personalized medicine, also called precision or individualized medicine, is a rapidly growing medical field. It focuses on improving the diagnosis, treatment and prevention of disease based on clues found in a persons genes.

In addition to determining your physical traits, such as eye color and height, your genes have an enormous effect on your health. Collecting information about your genes through genetic testing can provide you and your health care providers with valuable medical information.

Several kinds of genetic testing are available. Some tests are specific to inherited diseases and conditions, such as cystic fibrosis or sickle cell anemia. Other tests can check for genetic changes or variants (sometimes called mutations) that make it more likely you might develop a condition, such as breast cancer or blood clots.

A newer kind of genetic test called whole-genome sequencing goes beyond individual medical conditions and provides detailed information about all of a persons genetic code. Along with data about health and medical care, whole-genome sequencing can reveal more information. Research is continuing to better understand all the information held in the human genome.

You may have heard about direct-to-consumer genetic testing through radio, TV or internet advertisements. In this type of testing, a consumer provides a saliva or cheek swab sample to the company without a health care provider. Some companies offer disease carrier status, health traits, wellness or ancestry and family origin information. These tests attempt to help consumers better understand how genes influence health and wellness, and may help them talk to their health care provider about conditions that can run in families. Some tests provide information for entertainment or enjoyment. Its important to know the difference.

The information gathered through clinical genetic testing can offer valuable insight into how health care can be tailored to fit an individuals specific needs. One area where a considerable amount of research is being performed is in the way a persons genetic makeup may affect how his or her body responds to certain medications.

For example, for the common prescription pain medication tramadol to work effectively, the body has to process it to an active form. If your body cant process the medication due to your genetic makeup, you may not get pain relief from that drug.

Another example of genetic testing helps identify a cancer tumors genomic profile something like a fingerprint. Then, cancer therapies can be selected based on that tumors variants. This enables your health care provider to choose a medication that targets the tumor more effectively.

Although that example sounds straightforward, the connection between medication effectiveness and genes is like most topics associated with genetics quite complex and requires a great deal of research. Mayo Clinic researchers are exploring how the information gleaned from genetic testing can further inform the process of medication prescription.

Right now, individualized medicine is focused largely on customizing medical diagnosis, treatment and prevention based on a persons genes. But, in time, the field is likely to progress beyond genetics. Research is under way thats examining how the community of bacteria that live within a person the microbiome could affect certain diseases.

As individualized medicine moves forward, the goal is to personalize health care in such a way that each person receives optimal care thats crafted to suit his or her unique situation and needs.

Go here to see the original:

Personalized medicine focuses on patients' genetic clues - Newsday

Scientists provide insight into genetic basis of neuropsychiatric disorders – Medical Xpress

July 21, 2017 Credit: CC0 Public Domain

A study by scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) is providing insight into the genetic basis of neuropsychiatric disorders. In this research, the first mouse model of a mutation in the arid1b gene was created and then used to show that growth hormone treatments reverse some manifestations of the mutation.

The ARID1B gene is one of the most commonly mutated genes in patients with intellectual disability and autism spectrum disorders, but scientists have not yet discerned if and how defects in the ARID1B gene contribute to these clinical manifestations. To understand how reduced levels of the protein product of the gene might cause these disorders, a team of researchers led by Dr. Hao Zhu and including graduate student Cemre Celen genetically modified mice to carry a mutation in one of two copies of the ARID1B gene. This mutation replicates the genetics of Coffin-Siris syndrome, a disorder that some patients with defects in the ARID1B gene have that is characterized by speech and social development problems, intellectual disability, and delayed physical growth.

The hope is that by understanding the molecular basis of Coffin-Siris syndrome, scientists will gain a deeper understanding of more common diseases involving intellectual and social impairment.

Scientists found mice with the mutated ARID1B gene exhibited the same type of physical and social changes seen in children with Coffin-Siris syndrome, such as abnormal brain development, muscle weakness, and increased anxiety and fear. The mice also displayed features consistent with autism spectrum disorder, such as social interaction abnormalities, repetitive behaviors, and abnormal "squeaks" or vocalizations. Further testing found these mice had lower-than-expected growth hormone and insulin-like growth factor (IGF1) levels in the blood, potentially explaining the small stature and delayed development seen in human patients. Treating mutant mice with growth hormones restored body size and muscle function, but did not significantly change the behaviors associated with the syndrome.

"These results suggest that growth hormone treatment could be a useful therapy for ARID1B patients. This is an interesting finding because we know some pediatricians already treat Coffin-Siris patients with growth hormones, although they were unaware that this response might be common to many people with ARID1B mutations," said Dr. Zhu, an Assistant Professor at CRI with joint appointments in Internal Medicine and Pediatrics at UT Southwestern Medical Center and a CPRIT Scholar in Cancer Research.

Dr. Zhu said he believes the study provides the scientific community with an important animal model to further investigate ARID1B's role in human brain disorders and will be a useful tool for therapeutic testing of potential treatments for autism, intellectual disability, and Coffin-Siris syndrome.

Explore further: Mice provide insight into genetics of autism spectrum disorders

More information: Cemre Celen et al. Arid1b haploinsufficient mice reveal neuropsychiatric phenotypes and reversible causes of growth impairment, eLife (2017). DOI: 10.7554/eLife.25730

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:

Scientists provide insight into genetic basis of neuropsychiatric disorders - Medical Xpress

Recruiting for autism study – WTAJ

An area health system is recruiting people with autism and their families for a nationwide genetics study.Geisinger's Autism and Developmental Medicine Institute (ADMI) has been awarded a one-year $150,000 grant for the research. The grant is renewable for a full three year term.

Children's Hospital of Philadelphia, Boston Children's Hospital and the UCLA Center for Autism are also taking part in the study. Researchers hope to enroll 50,000 people and use their medical and genetic data to better understand autism.

Approximately 50 genes, believed to play a role in autism, have been identified and Geisinger says researchers estimate that at least 300 more are involved. But many more samples are needed from those with autism and their immediate families.

ADMI Associate Director Brenda Finucane said, "we do a lot of family studies to look at just people's genetic makeup and then when a child is born with a particular change in their genetic makeup, how the family background genes are influencing the way it plays out."

To participate in the study contact Kate Dent at 570-522-9402 or email her at kadent@geisinger.edu.

Originally posted here:

Recruiting for autism study - WTAJ

Edmond geneticist earns National Mentorship Award – Edmond Sun

The American Society of Human Genetics has awarded OU Childrens Physicians Geneticist John J. Mulvihill, M.D., of Edmond, its 2017 Mentorship Award. Mulvihill holds the Childrens Hospital Foundations Kimberly V. Talley Chair in Genetics and is also a professor of Pediatrics at the University of Oklahoma College of Medicine.

He is also a senior consultant to the division of Genomic Medicine in the National Human Genome Research Institute, part of the National Institutes of Health.

The ASHG Mentorship Award recognizes members who have significant records of accomplishment as mentors. It is open to individuals at all academic ranks who have shown a sustained pattern of exemplary mentorship at the graduate, postdoctoral, residency or fellowship level. The award presentation, which includes a plaque and $10,000 prize, will take place on Friday, Oct. 20, during the organizations 67th Annual Meeting in Orlando, Fla.

Its an incredible honor for me to accept this recognition from my colleagues and outstanding mentees, whose careers and lives Ive been privileged to touch, Mulvihill said. Mentorship in genetics, science and medicine is a life-long duty and joy.

Over the years, Mulvihill has founded multiple successful genetics training programs across the country, and has personally mentored trainees across fields and career stages through these programs. In 1983, while serving as clinical genetics section chief in the National Cancer Institutes Clinical Epidemiology Branch, he helped launch the NIH Interinstitute Medical Genetics Training Program, which he directed until 1989. He then founded the department of Human Genetics at the University of Pittsburgh, where he served as professor and co-director of the Pittsburgh Genetics Institute until 1998.

That same year, he founded the section of Pediatric Genetics at the OU College of Medicine, where he later established the Medical Genetics Residency Program and the masters program in Genetic Counseling. His research has focused on the genetics of human cancer, particularly late genetic and reproductive effects in cancer survivors and germ cell mutagenesis.

Read more:

Edmond geneticist earns National Mentorship Award - Edmond Sun

Genetic Susceptibility to Alzheimer’s May Increase Sleep-Disordered Breathing Cognitive Impairment – Newswise (press release)

Newswise July 18, 2017People who carry a genetic susceptibility to Alzheimers disease appear to be at greater risk of diminished cognition from sleep-disordered breathing than those without the susceptibility, according to new research published online, ahead of print in the Annals of the American Thoracic Society.

In Greater Cognitive Deficits with Sleep-Disordered Breathing among Individuals with Genetic Susceptibility to Alzheimers Disease: The Multi-Ethnic Study of Atherosclerosis, researchers report that study participants carrying the apolipoprotein -4 (APOE-4) allele showed greater cognitive deficits with the various indices of sleep-disordered breathing compared to those without the allele.

APOE is a major cholesterol carrier that supports injury repair in the brain. Other studies have shown that those carrying the alternate form of the gene, 4 allele, are at increased risk of Alzheimers disease. Estimates are that 20 percent of the population carries the 4 allele.

Previous studies have shown inconsistent findings between sleep-disordered breathing and cognition, which may be due to the different tests used, said lead study author Dayna A. Johnson, PhD, MPH, MS, MSW, instructor of medicine at Brigham and Womens Hospital and Harvard Medical School. Dr. Johnson and colleagues investigated the association in a diverse sample using several indicators of sleep-disordered breathing and cognition. They also evaluated whether the presence of the APOE-4 allele, which is known to increase risk of Alzheimers disease, influenced the link between sleep-disordered breathing and cognition.

The authors analyzed data from 1,752 participants (average age 68) in the Multi-Ethnic Study of Atherosclerosis (MESA) who underwent an in-home polysomnography (sleep) study, completed standardized sleep questions, and a battery of tests to measure their cognition. The authors defined sleep-disordered breathing as an apnea-hypopnea index (AHI), which measures the number of stopped or shallow breaths per hour, as AHI > 15, and sleep apnea syndrome as AHI > 5 (below 5 is normal) plus self-reported sleepiness (based on a standardized scale).

The study found:

The researchers adjusted for race, age, body mass index, education level, smoking status, hypertension, diabetes, benzodiazepine use, and depressive symptoms.

Dr. Johnson said that, overall, the effects of the various sleep factors they measured on cognition were small, but in the range previously reported for several other lifestyle and health risk factors for dementia. Screening and treating sleep-disordered breathing, she added, may help reduce a persons risk of dementia, especially if that individual carries APOE-4.

Our study provides further evidence that sleep-disordered breathing negatively affects attention, processing speed and memory, which are robust predictors of cognitive decline, said senior study author Susan Redline, MD, MPH, Peter C. Farrell Professor of Sleep Medicine, Harvard Medical School. Given the lack of effective treatment for Alzheimers disease, our results support the potential for sleep-disordered breathing screening and treatment as part of a strategy to reduce dementia risk.

The Multi-Ethnic Study of Atherosclerosis was funded by the National Heart, Lung, and Blood Institute, which also funded various aspects of the current study.

Contact for Article

Dayna A. Johnson PhD, MPH, MS, MSW

Email: djohnson@research.bwh.harvard.edu

Share via Twitter

Genetic susceptibility to #Alzheimers increases chance that poor #sleep will impair attention, memory and cognitive processing.

Follow Us

ATS - @atscommunity

AJRCCM - @AnnalsATSEditor

About the Annals of the American Thoracic Society (AnnalsATS)

The AnnalsATS is a peer-reviewed journal published by the American Thoracic Society. The journal delivers up-to-date and authoritative coverage of adult and pediatric pulmonary and respiratory sleep medicine and adult critical care. The scope of the journal encompasses content that is applicable to clinical practice, the formative and continuing education of clinical specialists and the advancement of public health. Editor: David Lederer, M.D., M.S., associate professor of medicine and epidemiology and associate division chief for clinical and translational research at Columbia University.

About the American Thoracic Society

Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Societys 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.

The ATS will hold its 2018 International Conference, May 18-23, in San Diego, California, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.

###

Read more:

Genetic Susceptibility to Alzheimer's May Increase Sleep-Disordered Breathing Cognitive Impairment - Newswise (press release)

Pathologist Expert: Precision Medicine Could Still Deliver Good News for Sen. McCain – Newswise (press release)

Sen. John McCains glioblastoma diagnosis is bleak, but not hopeless, according to Dr. Eyas Hattab, Chair of the College of American Pathologists Neuropathology Committee. Personalized medicine holds the key to the tests that pathologists will be conducting this week and beyond. The two groups of glioblastoma tumors appear identical under the microscope, but genetics determine a patients course of treatment.

Personalized medicine today allows for the classification of glioblastomas into two main categories based on their genetic makeup, Dr. Hattab said. About 90 percent of glioblastomas are bad actors, usually with survival periods under 1 year while the remainder may live for about 5 years or longer. In addition to rendering the diagnosis of glioblastoma, the role of the pathologist is to determine to which genetic group a patient belongs.

While these tumors appear identical under the microscope, a tumors response to therapy differs from one patient to another depending on certain molecular characteristics. Through molecular testing, the laboratory is able to predict which tumors will respond better to certain chemotherapeutic and radiation therapies.

Read the original post:

Pathologist Expert: Precision Medicine Could Still Deliver Good News for Sen. McCain - Newswise (press release)

Pharmacogenomics Is Ushering in a New Era of Personalized Prescriptions – Healthline

Genetic testing and DNA blood sampling are providing medical professionals with ways to personalize drugs they give to their patients for a number of ailments.

Each of us metabolizes drugs in different ways because everyone has genetic variations.

For some, that can mean an otherwise effective prescription can pose unknown, even life-threatening risks.

Now, you can help protect yourself with DNA test kits that will tell you if you might have a genetic risk for certain diseases.

In April, the U.S. Food and Drug Administration (FDA) approved for the first time the direct-to-consumer marketing of a home DNA test kit.

Available from the company 23andMe, it allows consumers to test for 10 diseases, including Parkinsons, Alzheimers, and some rare blood diseases.

Genetic testing and the flourishing field of pharmacogenomics which studies how a persons genes affect the way they respond to drugs, such as beta-blockers or statins is making a revolutionary age of individualized medicine possible.

Dr. Richard Weinshilboum, whom some have called the father of pharmacogenomics, has been a pioneer in this field of research for three decades.

Hes also an internist, professor of medicine and pharmacology, as well as co-medical director of the pharmacogenomics program at the Mayo Clinic Center for Individualized Medicine.

I work on cancer, and when you say genetic testing the public goes immediately to cancer, Weinshilboum told Healthline. But with pharmacogenomics, youre talking about all of medicine.

The concept of pharmacogenomics is more than 50 years old, he said, and the whole idea of genetic diagnosis is one big mix master bowl. Genetic testing is the result of the Human Genome Project, and all of this research is a race to the starting line.

Weinshilboum grew up in a small town in southern Kansas, where the town doctor, a general practitioner, lived next door.

He gave most of his patients placebos and most of them got better, he said. Today, with DNA sequencing and pharmacogenomics, were entering the age of personalized medicine, where each patient will eventually receive the right drug at the right dosage.

Although Weinshilboums work is with cancer, he said individualized medicine has the potential to benefit people with everything from diabetes to depression.

The genomic revolution has immediate implications that will basically affect everyone everywhere, said Weinshilboum.

His work focuses on three clinical goals: maximizing drug efficacy, selecting responsive patients, and avoiding adverse drug reactions.

Two dramatic cases involving a newborn baby and a woman illustrate the dangers of genetic variation and adverse reactions to drugs.

Weinshilboum cited a deadly 2005 case in Canada:

A woman in Toronto delivered a normal baby boy, but the baby was not thriving. She had been prescribed Tylenol with codeine for post-delivery episiotomy pain. She breastfed her newborn, but he was not feeding well. Her baby died at 12 days old, Weinshilboum recounted.

Codeine must be metabolized into morphine before it can begin to relieve pain, Weinshilboum said.

Tests of the mothers milk revealed she had a genetic variation that caused her body to create a greater than normal volume of morphine when it processed the codeine, he said. The morphine in her milk caused her baby to stop breathing.

About 5 percent of women have this genetic defect. Women with this genetic abnormality who take codeine while breastfeeding expose their infants to high, possibly even toxic levels of morphine through their breast milk.

The other case occurred in 2009, when Karen Daggett of Minnesota and her husband, while visiting Florida, went on a Valentines Day date.

While on their date, she felt dizzy and nearly passed out. Prescription medicines she had been taking for an irregular heartbeat had accumulated in her body to a toxic level. She was rushed to an emergency room.

I had been on various blood pressure meds and beta-blockers since my mid 30s and Im 71 now, Daggett told Healthline.

Daggetts only warning came when she had ended up in the emergency room the year before.

I had experienced milder symptoms as long as 40 years ago, but by the time I arrived at an ER, I would be back in normal heart rhythm, so nothing was documented or recorded, she said.

Emergency physicians gave Daggett two additional medications, and she was placed in intensive care with a racing heart and extremely high blood pressure.

They changed my meds again and within two days I was back in ER with the same symptoms, so they cut the drug in half, she said. I felt so miserable I went to Mayo Clinic, where I underwent a heart ablation in December 2008. [Ablation scars or destroys heart tissue that triggers or sustains an abnormal heart rhythm.] I was then put on the normal post-ablation medications, five of them, and joined a Lipitor [lipid-lowering statin] drug study.

Daggett still felt really weak and terrible, but thought that was a temporary result of the surgery.

Then back to that 2009 trip to Florida Daggett was treated for four days without success and then taken to the Mayo Clinic where she underwent nine days of tests.

Her primary physician, Dr. Lynne Shuster, worked with her Mayo cardiologist, Dr. Hon-Chi Lee. They took Daggett off all meds and tried new ones that would be processed through her kidneys, not her liver.

Still, the physicians didnt find any answers.

Then Shuster ordered pharmacogenomic testing, trying to discover if something in Daggetts genetic makeup was affecting the way she processed medications.

Dr. Shuster thought outside the box, Daggett said. They found an enzyme that metabolizes many, many drugs, including cardiac drugs, but was genetically missing in me. What a gift.

Daggetts family has since learned that 23 members of her family, covering four generations, have some variation of the liver enzymatic deficiencies, she said.

Daggett, who has been taking a safer heart medication since her genetic testing at the Mayo Clinic in early 2009, goes back for a yearly checkup.

Wherever she travels, Daggett carries with her a briefcase with her blood work files, in case she ever has to visit a physician.

Most important is that I am alive to see two great grandbabies, and to share this information with others, in the hope that they can avoid the pain and fear I experienced, she said. I raised eight children and have 23 grandkids. I am hopeful that this pain has had a purpose. I am alive because of Mayo Clinic Research. For that I am forever grateful.

Dr. Alan Wu, medical director of the pharmacogenomics lab at the University of California, San Francisco, educates physicians and students about the value of pharmacogenomic tests, and of performing clinical studies that demonstrate the value of this type of testing.

We are currently performing a study on Plavix, an antiplatelet drug used after patients have undergone angioplasty, he told Healthline. Individuals who are poor metabolizers for this pro-drug have higher rates of restenosis [recurring abnormal narrowing of an artery or valve after corrective surgery] and myocardial infarction [heart attack].

There is an alternate [on patent] antiplatelet drug that can be used, however it is costs more than Plavix, he added. Because individuals who are Asian or Pacific Islander have a much higher incidence of poor metabolism than Caucasians, this test is particularly relevant here.

What are the limitations of pharmacogenomic testing?

The costs are considerably higher than for other types of clinical laboratory tests such as a complete blood count or a blood glucose exam, Wu said.

There are also privacy concerns for performing genetic testing.

Wu said pharmacogenomic testing refers to predicting the efficacy and toxicity avoidance of a particular drug on a particular individual.

Because it does not diagnose genetic diseases, there is no stigma associated with testing, he said. It is akin to revealing that someone has a peanut allergy. The current limitation is convincing doctors to order these tests.

Pharmacogenomic tests have another important use besides testing for heart disease, cancer, and depression.

Specialists are increasingly using the testing for pain management.

Many of the medications used for analgesia are not effective for individuals who are poor metabolizers, Wu said. Other pharmacogenomics tests can be used for psychiatric patients on antidepressive medications. Newer tests are being discovered each year.

The Mayo Clinic got involved in the test business in 2014, when it founded OneOme with Invenshure, a Minneapolis-based incubator and venture catalyst.

In the interest of full disclosure, Weinshilboum pointed out that he was one of the company founders, and that Mayo invested in the enterprise.

OneOme is a genomics interpretation company that uses Mayos considerable knowledge in pharmacogenomics. Their test, RightMed, is a take-home, physician-ordered analysis that sells for $249.

The test analyzes an individuals DNA to predict their response to medications.

OneOme can run the genotype test for sequence variants in several of the more common genes that can alter drug response, Weinshilboum said. The company also supplies a report for the physician that separates drugs into those the patient can take in the usual FDA-approved dose, and those that might not work, or which could result in an adverse reaction in that particular patient. But I should emphasize that the report is meant for the physician to use to treat the patient.

The results of pharmacogenomics testing can be integrated into a patients electronic medical record.

DNA does not change, so you dont have to repeat the test, Weinshilboum said. The information follows patients wherever they go, and can serve as a lifelong resource for making effective prescription decisions.

See original here:

Pharmacogenomics Is Ushering in a New Era of Personalized Prescriptions - Healthline

Restoring Cognitive Function for Alzheimer’s Disease – UB School of Medicine and Biomedical Sciences News

Researchers in the Department of Physiology and Biophysics are studying genetic and epigenetic factors in Alzheimers disease to develop novel ways of restoring function to patients in the later stages of the neurodegenerative disorder.

While most research on Alzheimers has focused on early diagnosis and treatment, the new study is focusing on finding novel ways to restore cognitive function and will utilize studies in mouse models carrying gene mutations for familial Alzheimers (where more than one family member has the disease) and in human stem cell-derived neurons from Alzheimers patients.

The work involving preclinical research to unravel genetic and epigenetic factors that cause Alzheimers is funded by a five-year, $2 million grant from the National Institutes of Healths National Institute on Aging. Zhen Yan, PhD, professor of physiology and biophysics, is principal investigator.

Epigenetic factors can change gene expression without altering the underlying DNA sequence which in turn affects how cells read the genes. Such changes may profoundly impact human health.

We hypothesize that Alzheimers is produced by a combination of genetic risk factors and environmental factors, such as aging, that induce the dysregulation of specific epigenetic processes that lead to impaired cognition, Yan says.

The research will explore how epigenetic changes that accompany Alzheimers disease also might help identify a much sought-after biomarker for the disease, which could allow for novel treatment.

Numerous clinical trials in recent years have focused on reducing amyloid beta plaque in the brain. So far, such efforts havent yet translated into improving cognitive function, Yan says.

Our research, by contrast, will target synaptic function, which is at the root of cognitive function, she explains. Our hypothesis is that this approach will have a more fundamental effect.

Yan and her colleagues will investigate aberrant histone methylation, an epigenetic process that affects the expression of genes encoding key proteins that allow for signals to be transmitted between neurons.

When this process is dysregulated in Alzheimers disease, neuronal signaling doesnt function properly, leading to cognitive impairment.

Even though Alzheimers patients can often easily remember something that happened 20 years ago, the later stages of the disease are characterized by a growing inability to recall recently learned information.

That kind of short-term working memory, Yan explains, is dependent on excitatory transmission in the frontal cortex, mediated by glutamate receptors.

At the later stages of the disease, we know that there is a loss of glutamate receptors that are crucial for learning and memory, she says. When these receptors lose the ability to communicate, there is a loss of cognition.

Our research will try to restore gene expression in these glutamate receptors using epigenetic tools, with the ultimate goal of restoring cognitive function.

Jian Feng, PhD, professor of physiology and biophysics, is a co-investigator on the grant titled A Novel Epigenetic Mechanism for Alzheimers Disease.

Go here to read the rest:

Restoring Cognitive Function for Alzheimer's Disease - UB School of Medicine and Biomedical Sciences News

How genetics will impact the future of sports medicine: Dr. Michael Swartzon’s insights – Becker’s Orthopedic & Spine

Historically, genetics researchers have not dedicated time to the orthopedic field, instead focusing on oncology, infectious diseases and cardiovascular diseases.

"Orthopedics is usually quite simple; a bone is broken, you splint it and let it heal," explains Michael Swartzon, MD, of Miami Orthopedics & Sports Medicine Institute at Baptist Health South Florida. "I think that's why orthopedics wasn't a bigger player earlier on in using genetics."

This may be changing, however, as sports medicine physicians realize the power of genetics and environmental data in injury prevention.

Dr. Swartzon and colleagues published a review in Strength and Conditioning Journal on precision sports medicine. The review argues how leveraging information from an individual's genetics, environment, lifestyle and epigenetics could help providers "maximize resources by targeting pathology and human performance on the molecular level."

Dr. Swartzon sees promise in using an individual's genetic information to determine various contributors to performance, such as muscle fiber composition. Equipped with genetic information, physicians may be able to predict who is prone to arthritis or who may dehydrate faster.

"There are many areas in which we could use genetics for elite athletes to advance their performance," says Dr. Swartzon. In addition to performance, genetics will play a critical role in athlete safety.

"When you look at what you're trying to do as a physician, preventing people from fatal injuries is the top priority," Dr. Swartzon adds. Although genetic tests are available to determine whether athletes are at greater risk of conditions, like cardiac issues, Dr. Swartzon emphasizes the controversy surrounding such tests. The decision lies in whether young athletes should refrain from playing basketball, for instance, since they test positive for a gene related to cardiac issues.

"Just because you have the gene for something, doesn't mean you actually get it," he says.

Although preventative genetic testing for sports involvement is still under debate, Dr. Swartzon highlights pharmacogenomics as a hot research field. Pharmacogenomics involves leveraging genetic information to predict how a person will respond to a medication. The process could help identify which medication and dose will prove more effective for a particular person.

Further, with orthobiologics gaining steam in the orthopedics field, Dr. Swartzon sees genetics entering the game to determine who should receive treatments.

"That's where the research comes in, and hopefully the question of why and which person will be answered by genetics," he adds.

Genetics will help physicians forgo treatments they know will not work for individual patients, reduce side effects and ultimately, speed recovery.

More articles on sports medicine: Dr. Keith Meister to perform Tommy John surgery on Nationals' Joe Ross 4 insights Dr. Marc Philippon performs hip surgery on A's player: 4 takeaways LA Chargers name Hoag Memorial Hospital Presbyterian the official healthcare provider: 4 observations

See original here:

How genetics will impact the future of sports medicine: Dr. Michael Swartzon's insights - Becker's Orthopedic & Spine

Promising therapy for fatal genetic diseases in children nears human trials – Medical Xpress

July 18, 2017

Researchers at University of Massachusetts Medical School and Auburn University College of Veterinary Medicine are nearing human clinical trials on a genetic therapy for two rare neurological diseases that are fatal to children.

The scientists are seeking approval from the U.S. Food and Drug Administration (FDA), to test a gene therapy treatment for Tay-Sachs and Sandhoff diseases, genetic disorders in a category known as lysosomal storage diseases.

Tay-Sachs and Sandhoff are inherited neurologic diseases that occur when genetic mutations prevent cells from producing enzymes needed to break down and recycle materials. Without these enzymes, the materials accumulate to toxic levels, slowly destroying the nervous system. The researchers are working on a gene therapy to correct the enzyme deficiency using adeno-associated virus, or AAV, vectors.

The average life expectancy for children with infantile Tay-Sachs or Sandhoff disease is only 3 to 5 years. There is currently no treatment. The gene therapy in development has shown promise in animal models of these diseases by extending lifespans by up to four times those of untreated animals.

"The proof-of-concept studies in affected animals are compelling, and the FDA provided a clear path of remaining experiments needed to seek approval for human clinical trials," said Douglas R. Martin, a professor at Auburn University's College of Veterinary Medicine. "We now need the funding to complete the studies."

The animal phase of toxicity studies necessary to demonstrate the safety of the gene therapy for Tay-Sachs and Sandhoff diseases has been completed with the support of the National Tay-Sachs & Allied Disease Association and the Cure Tay-Sachs Foundation.

"Too many children with Tay-Sachs and Sandhoff have died since we started this project. The time has finally arrived to push back on these diseases," says Miguel Sena-Esteves, PhD, associate professor of neurology at UMass Medical School. "Our single-minded goal is to get a safe and potentially effective therapy to patients and their families as quickly as possible."

"Hopefully, once the news gets out that we are this close to human clinical trials, fundraising efforts will be sufficient so we can complete the IND-enabling studies and proceed to human clinical trials," said veterinarian Heather Gray-Edwards, an assistant professor at Auburn University College of Veterinary Medicine.

Additional funding of $1.2 million is being sought to complete the safety studies, fund the production of clinical grade AAV, and complete regulatory filings.

Explore further: Promising results with new gene therapy approach for treating inherited neurodegenerative diseases

Transplantation of therapeutic stem cells directly into the central nervous system (CNS) is a promising new approach to treating the neurological effects of lysosomal storage diseases (LSD), a group of at least 50 different ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Excerpt from:

Promising therapy for fatal genetic diseases in children nears human trials - Medical Xpress

Scientists one step close to cure for dementia after genetic medical breakthrough – Mirror.co.uk

Scientists are closer to finding a cure for dementia after discovering two genes which raise your risk.

Researchers behind the exciting discovery hope it will lead to new treatments for the condition which currently affects more than half a million people in the UK, according to the Alzheimers Society, and is the leading cause of dementia.

Dr Doug Brown, director of research and development at the Society which jointly funded the work, said: Over 60% of people with dementia have Alzheimers disease, yet despite its prevalence we still dont fully understand the complex causes of the disease.

The discovery of two new risk genes for Alzheimers is an exciting advance that could help to deepen our understanding of what happens in the brains of people with the disease.

These genes reinforce a critical role for special cells in the brain - called microglia - that are responsible for clearing up debris including damaged cells and proteins.

Dr Brown said such findings helped to show researchers where to focus their efforts in the search for new, effective treatments.

The researchers from Cardiff University received funding from the Medical Research Council (MRC), Welsh Government and Alzheimers Research UK.

They identified the two genes, which were not previously considered candidates for Alzheimers risk, during a study which compared the DNA of tens of thousands of individuals with Alzheimers with aged-matched people who are free from the disease, building on their previous work of identifying 24 susceptibility genes.

Dr Rebecca Sims, from Cardiff Universitys School of Medicine, said the genes, which suggested immune cells in the brain played a causal role in the disease, were very good targets for potential drug treatment.

She added: In addition to identifying two genes that affect the risk of developing Alzheimers disease, our new research reveals a number of other genes and proteins that form a network likely to be important in its development.

The University was selected as one of six centres for the 250m UK Dementia Research Institute in April and the team there will now build on this discovery to investigate in detail the role of microglia in dementia, which Dr Brown said will ultimately accelerate our progress towards finding a cure.

The centre, which will employ up to 60 researchers in the first five years of the initiative and with the potential to be awarded further funding is set to become the biggest investment Wales has ever received for scientific study into dementia.

Dr Rosa Sancho, who is head of research at Alzheimers Research UK, likened the revelations to finding puzzle pieces that biologists can start to fit together to build a complete picture of a disease.

She said: There are currently no treatments to slow the progression of Alzheimers and increased investment in research is vital so that we can capitalise on new findings and drive progress for people with the condition and their families.

The research Rare coding variants in PLCG2, ABI3 and TREM2 implicate microglial-mediated innate immunity in Alzheimers disease is published in Nature Genetics.

Read the rest here:

Scientists one step close to cure for dementia after genetic medical breakthrough - Mirror.co.uk